<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="147945">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01826487</url>
  </required_header>
  <id_info>
    <org_study_id>PTC124-GD-020-DMD</org_study_id>
    <nct_id>NCT01826487</nct_id>
  </id_info>
  <brief_title>Phase 3 Study of Ataluren in Patients With Nonsense Mutation Duchenne Muscular Dystrophy</brief_title>
  <acronym>ACT DMD</acronym>
  <official_title>A Phase 3 Efficacy and Safety Study of Ataluren (PTC124) in Patients With Nonsense Mutation Dystrophinopathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PTC Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PTC Therapeutics</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dystrophinopathy is a disease continuum that includes Duchenne muscular dystrophy, which
      develops in boys. It is caused by a mutation in the gene for dystrophin, a protein that is
      important for maintaining normal muscle structure and function. Loss of dystrophin causes
      muscle fragility that leads to weakness and loss of walking ability. A specific type of
      mutation, called a nonsense (premature stop codon) mutation is the cause of dystrophinopathy
      in approximately 10-15% of boys with the disease. Ataluren is an orally delivered,
      investigational drug that has the potential to overcome the effects of the nonsense
      mutation. The main goal of this Phase 3 study is to evaluate the effect of ataluren on
      walking ability.  The effect of ataluren on physical function, quality of life, and
      activities of daily living will be evaluated.  This study will also provide additional
      information on the long-term safety of ataluren.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to
      determine the efficacy and safety of ataluren 10, 10, 20 mg/kg in patients with
      nonsense-mutation (nm) dystrophinopathy. Patients will be randomized in a 1:1 ratio to
      ataluren 10-, 10-, 20-mg/kg dose level or placebo. Patients will receive study drug TID at
      morning, midday, and evening. It is planned that 220 patients will be enrolled and patients
      will undergo 48 weeks of blinded treatment prior to the final analysis. Study assessments
      will be performed at clinic visits every 8 weeks.  It is anticipated that an open-label
      extension study will be available to patients (who successfully complete the double-blind
      study) in countries where ataluren is not commercially available.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Changes in the distance walked during a 6-minute walk test</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Physical function</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>North Star Ambulatory Assessment and Timed Function Testing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient and/or parent-reported activities of daily living and disease symptoms</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Safety profile characterized by type, frequency, severity, timing, and relationship to study drug of any adverse events, or of abnormalities of laboratory tests, vital signs, physical examinations, or ECGs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ataluren blood levels</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance</measure>
    <time_frame>Baseline and 48 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Muscular Dystrophy, Duchenne</condition>
  <condition>Muscular Dystrophies</condition>
  <condition>Muscular Disorders, Atrophic</condition>
  <condition>Muscular Diseases</condition>
  <condition>Musculoskeletal Diseases</condition>
  <condition>Neuromuscular Diseases</condition>
  <condition>Nervous System Diseases</condition>
  <condition>Genetic Diseases, X-Linked</condition>
  <condition>Genetic Diseases, Inborn</condition>
  <arm_group>
    <arm_group_label>Ataluren</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>10, 10, 20 mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ataluren</intervention_name>
    <arm_group_label>Ataluren</arm_group_label>
    <other_name>PTC124</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to provide written informed consent (parental/guardian consent if
             applicable)/assent per local requirements.

          -  Male sex.

          -  Age ≥7 and ≤16 years.

          -  Phenotypic evidence of dystrophinopathy based on the onset of characteristic clinical
             symptoms or signs (eg. proximal muscle weakness, waddling gait, and Gowers' maneuver)
             by 6 years of age, an elevated serum creatinine kinase level, and ongoing difficulty
             with walking.

          -  Documentation of the presence of a nonsense point mutation in the dystrophin gene as
             determined by gene sequencing from a laboratory certified by the College of American
             Pathologists (CAP), the Clinical Laboratory Improvement Act/Amendment (CLIA) or an
             equivalent organization.

          -  Documentation that a blood sample has been drawn for confirmation of the presence of
             a nonsense mutation in the dystrophin gene.

          -  Use of systemic corticosteroids (prednisone, prednisolone, or deflazacort) for a
             minimum of 6 months immediately prior to start of study treatment, with no
             significant change in dosage or dosing regimen (not related to body weight change)
             for a minimum of 3 months immediately prior to start of study treatment and a
             reasonable expectation that dosage and dosing regimen will not change significantly
             for the duration of the study.

          -  Ability to walk ≥150 meters unassisted during the screening 6-minute walk test.
             Patients need to be below the protocol-specified threshold for %-predicted 6MWD.

          -  Results of the 2 Baseline 6MWD results must be determined as valid and results of the
             Day 2 Baseline 6MWD must be within 20% of the Day 1 Baseline 6MWD.

          -  Baseline 6MWD (mean of valid Day 1 and Day 2 values) must be no more than a 20%
             reduction from the valid Screening 6MWD.

          -  Confirmed screening laboratory values within the central laboratory ranges (hepatic,
             renal, and serum electrolyte parameters)

          -  Willingness to abstain from sexual intercourse or employ an approved method of
             contraception during the period of study drug administration and 6-week follow-up
             period.

          -  Willingness and ability to comply with scheduled visits, drug administration plan,
             study procedures, laboratory tests, and study restrictions.

        Exclusion Criteria:

          -  Treatment with systemic aminoglycoside antibiotics within 3 months prior to start of
             study treatment.

          -  Initiation of systemic corticosteroids therapy within 6 months prior to start of
             study treatment.

          -  Change in systemic corticosteroid therapy (eg, change in type of drug, dose
             modification not related to body weight change, schedule modification, interruption,
             or reinitiation) within 3 months prior to start of study treatment.

          -  Any change (initiation, change in type of drug, dose modification, schedule
             modification,interruption, discontinuation, or reinitiation) in prophylaxis/treatment
             for congestive heart failure (CHF) within 3 months prior to start of study treatment.

          -  Ongoing use of coumarin-based anticoagulants (eg. warfarin), phenytoin, tolbutamide,
             or paclitaxel.

          -  Prior therapy with ataluren.

          -  Known hypersensitivity to any of the ingredients or excipients of the study drug

          -  Exposure to another investigational drug within 3 months prior to start of study
             treatment.

          -  History of major surgical procedure within 6 weeks prior to start of study treatment.

          -  Ongoing immunosuppressive therapy (other than corticosteroids).

          -  Ongoing participation in any clinical trial (except for studies specifically approved
             by PTC Therapeutics).

          -  Expectation of major surgical procedure (eg, scoliosis surgery) during the 12-month
             treatment period of the study.

          -  Requirement for daytime ventilator assistance. Note: Evening ventilator assistance
             and use of bi-level positive airway pressure (Bi-PAP) therapy is allowed.

          -  Uncontrolled clinical symptoms and signs of CHF (American College of
             Cardiology/American Heart Association Stage C or Stage D).

          -  Prior or ongoing medical condition (eg, concomitant illness, psychiatric condition,
             behavioral disorder, alcoholism, drug abuse), medical history, physical findings (eg.
             lower limb injury that may affect 6MWT performance), ECG findings, or laboratory
             abnormality that, in the investigator's opinion, could adversely affect the safety of
             the subject, makes it unlikely that the course of treatment or follow-up would be
             completed, or could impair the assessment of study results.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Spiegel, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>PTC Therapeutics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Diane Goetz</last_name>
    <phone>908-912-9256</phone>
    <email>dgoetz@ptcbio.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diane Goetz</last_name>
    <phone>866-282-5873</phone>
    <email>patientinfo@ptcbio.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angel Hu</last_name>
      <phone>310-825-3264</phone>
      <email>angelhu@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Perry Shieh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UC Davis Medical Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Goude, BA CCRP</last_name>
      <phone>916-734-0968</phone>
      <email>erica.goude@ucdmc.ucdavis.edu</email>
    </contact>
    <investigator>
      <last_name>Craig McDonald, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Stanford University Medical Center</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305-5236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shirley Paulose</last_name>
      <phone>650-724-3792</phone>
      <email>spaulose@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>John Day</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Colorado - Center for Cancer and Blood Disorders</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Gibbons</last_name>
      <phone>720-777-3697</phone>
      <email>Melissa.Gibbons@childrenscolorado.org</email>
    </contact>
    <investigator>
      <last_name>Julie Parsons</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Child Neurology Center of Northwest Florida</name>
      <address>
        <city>Gulf Breeze</city>
        <state>Florida</state>
        <zip>32561</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynn Head</last_name>
      <phone>850-934-1299</phone>
      <email>lynn.head@cneurology.com</email>
    </contact>
    <investigator>
      <last_name>Ben Renfroe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Rohde</last_name>
      <phone>312-942-0079</phone>
      <email>susan_rohde@rush.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Heydemann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Iowa</name>
      <address>
        <city>Iowa City</city>
        <state>Iowa</state>
        <zip>52242</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carrie Stephan</last_name>
      <phone>319-356-2673</phone>
      <email>carrie-stephan@uiowa.edu</email>
    </contact>
    <investigator>
      <last_name>Katherine Mathews, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabrielle Rico</last_name>
      <phone>913-588-5703</phone>
      <email>grico@kumc.edu</email>
    </contact>
    <investigator>
      <last_name>Richard Barohn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital Boston</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Visyak</last_name>
      <phone>857-218-4677</phone>
      <email>Nicole.visyak@childrens.harvard.edu</email>
    </contact>
    <investigator>
      <last_name>Basil Darras, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cameron Naughton</last_name>
      <phone>612-625-4882</phone>
      <email>naug0009@umn.edu</email>
    </contact>
    <investigator>
      <last_name>Peter Karachunski, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine, Division of Endocrinology, Metabolism and Lipid Research</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betsy Malkus</last_name>
      <phone>314-362-1624</phone>
      <email>malkusb@neuro.wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Anne Connolly, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbia University College of Physicians &amp; Surgeons</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathan Marra</last_name>
      <phone>212-305-2461</phone>
      <email>jdm2132@columbia.edu</email>
    </contact>
    <investigator>
      <last_name>Jacinda Sampson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cincinnati Children's Hospital Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229-3039</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paula Morehart</last_name>
      <phone>513-636-8967</phone>
      <email>Paula.Morehart@cchmc.org</email>
    </contact>
    <investigator>
      <last_name>Brenda Wong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nationwide Children's Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43209</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Gailey</last_name>
      <phone>614-355-2897</phone>
      <email>Susan.Gailey@nationwidechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Kevin Flanigan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bryn McCarthy</last_name>
      <phone>503-418-8297</phone>
      <email>mccarbry@ohsu.edu</email>
    </contact>
    <investigator>
      <last_name>Erika Finanger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital of Philadelphia</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nancy Videon</last_name>
      <phone>267-426-7163</phone>
      <email>videon@email.chop.edu</email>
    </contact>
    <investigator>
      <last_name>Gihan Tennekoon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jennifer Monahan</last_name>
      <phone>412-692-5176</phone>
      <email>jennifer.monahan@chp.edu</email>
    </contact>
    <investigator>
      <last_name>Hoda Abdel-Hamid, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Childrens Medical Center Dallas, Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Kern</last_name>
      <phone>214-456-8755</phone>
      <email>sharon.kern@childrens.com</email>
    </contact>
    <investigator>
      <last_name>Susan Iannaccone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gloria Orozco</last_name>
      <phone>832-822-1804</phone>
      <email>gxorozco@texaschildrens.org</email>
    </contact>
    <investigator>
      <last_name>Tim Lotze, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Utah</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Missy Dixon</last_name>
      <phone>801-585-7606</phone>
      <email>missy.dixon@genetics.utah.edu</email>
    </contact>
    <investigator>
      <last_name>Russell Butterfield, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Children's Hospital - Childhood Cancer and Blood Disorders</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Christensen</last_name>
      <phone>206-884-2756</phone>
      <email>ana.christensen@seattlechildrens.org</email>
    </contact>
    <investigator>
      <last_name>Susan Apkon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Children's Hospital at Westmead</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carleen Fernandez</last_name>
      <phone>61 2 9845 3004</phone>
      <email>carleen.fernandez@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Kristi Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Royal Children's Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniella Villano</last_name>
      <phone>+61 (0)3 9345 4633</phone>
      <email>daniella.villano@rch.org.au</email>
    </contact>
    <investigator>
      <last_name>Monique Ryan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Corine Antonis</last_name>
      <phone>32 16 34 0250</phone>
      <email>corine.antonis@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Nathalie Goemans, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universidade Federal do Rio de Janeiro - Instituto de Puericultura e Pediatria Martagao Gesteira</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21.941-912</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sao Paulo University -HC/FMUSP</name>
      <address>
        <city>São Paulo</city>
        <zip>05403-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Aleksandrovska Hospital University</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Teodora Chamova</last_name>
      <phone>00359 889 802 252</phone>
      <email>teodoratch@abv.bg</email>
    </contact>
    <investigator>
      <last_name>Velina Guergueltcheva-Bliznakova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jordan Turley</last_name>
      <phone>587-226-8108</phone>
      <email>jordan.turley@albertahealthservices.ca</email>
    </contact>
    <investigator>
      <last_name>Jean Mah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>British Columbia Children's Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6H 3V4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nela Martic</last_name>
      <phone>604-875-2345</phone>
      <phone_ext>6549</phone_ext>
      <email>nmartic3@cw.bc.ca</email>
    </contact>
    <investigator>
      <last_name>Katherine Selby, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Children's Hospital of Western Ontario</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 2E3</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabeeh Alvi</last_name>
      <phone>519-619-2465</phone>
      <email>sabeeh.alvi@lhsc.on.ca</email>
    </contact>
    <investigator>
      <last_name>Craig Campbell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universidad Catolica</name>
      <address>
        <city>Santiago</city>
        <zip>8330073</zip>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcela Urzúa</last_name>
      <phone>569 93228312</phone>
      <email>maurzua@med.puc.cl</email>
    </contact>
    <investigator>
      <last_name>Raul Escobar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Luis Calvo Mackenna</name>
      <address>
        <city>Santiago, Región Metropolitana</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carolina Wellmann</last_name>
      <phone>569 88853589</phone>
      <email>carowelmita@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Ricardo Erazo Torricelli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Brno</name>
      <address>
        <city>Brno</city>
        <zip>635 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lenka Mrazova</last_name>
      <phone>+420 737 778 483</phone>
      <email>lenkamrazo@seznam.cz</email>
    </contact>
    <investigator>
      <last_name>Petr Vondracek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Motol University Hospital</name>
      <address>
        <city>Praha</city>
        <zip>150 06</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcela Hložánková</last_name>
      <phone>+42 022 4433360</phone>
      <email>m.hlozankova@centrum.cz</email>
    </contact>
    <investigator>
      <last_name>Martin Kudr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital de la Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Elisabeth Fontaine</last_name>
      <phone>33 (0)4 91 38 46 44</phone>
      <email>Marie-elisabeth.FONTAINE@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>Brigitte Chabrol, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes Cedex</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Raphaële Chasserieau</last_name>
      <phone>+33 2 40 08 78 80</phone>
      <email>raphaele.chasserieau@chu-nantes.fr</email>
    </contact>
    <investigator>
      <last_name>Yann Pereon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hopital Necker - Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kim-Hanh Le Quan Sang</last_name>
      <phone>33 1 44 49 59 51</phone>
      <email>kh.lequansang@nck.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Isabelle Desguerre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Groupe Hospitalier La Pitie-Salpetriere</name>
      <address>
        <city>Paris</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oumar Diebate</last_name>
      <phone>01 42 16 66 49</phone>
      <email>o.diebate@institut-myologie.org</email>
    </contact>
    <investigator>
      <last_name>Thomas Voit, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Essen-Duisburg</name>
      <address>
        <city>Essen</city>
        <zip>45122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baerbel Leiendecker</last_name>
      <phone>49 201 / 723-2508</phone>
      <email>baerbel.leiendecker@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Ulrike Schara, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Medical Center Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karin Schelb</last_name>
      <phone>049/761-270- 44740</phone>
      <email>karin.schelb@uniklinik-freiburg.de</email>
    </contact>
    <investigator>
      <last_name>Janbernd Kirschner, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Munich</name>
      <address>
        <city>Munich</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Astrid Blascheck</last_name>
      <phone>49 (0)89 5160 5110</phone>
      <email>astrid.blaschek@med.uni-muenchen.de</email>
    </contact>
    <investigator>
      <last_name>Wolfgang Mueller-Felber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hadassah University Hospital</name>
      <address>
        <city>Jerusalem</city>
        <zip>91240</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Debbie Krojanker Yaffe</last_name>
      <phone>972-52-287-05-02</phone>
      <email>debbiek@hadassah.org.il</email>
    </contact>
    <investigator>
      <last_name>Yoram Nevo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCS Ca Granda Ospedale Maggiore Policlinico di Milano</name>
      <address>
        <city>Milan</city>
        <zip>20122</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Francesca Magri</last_name>
      <phone>390255033807</phone>
      <email>francescam.magri@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Giacomo Comi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bambino Gesu Hospital</name>
      <address>
        <city>Rome</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe Pontrelli</last_name>
      <phone>+39 066859 3077</phone>
      <email>giuseppe.pontrelli@opbg.net</email>
    </contact>
    <investigator>
      <last_name>Enrico Bertini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O. Complessa di Neuropsichiatria Infantile</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Concetta Palermo</last_name>
      <phone>+39 0630 154 032</phone>
      <email>palermotitti@libero.it</email>
    </contact>
    <investigator>
      <last_name>Eugenio Mercuri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario G. Martino</name>
      <address>
        <city>Sicily</city>
        <zip>98125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sonia Messina</last_name>
      <phone>0039090 2217191</phone>
      <email>smessina@unime.it</email>
    </contact>
    <investigator>
      <last_name>Giuseppe Vita, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jisu Hong</last_name>
      <phone>82.2.2072.1652</phone>
      <email>kaya178916@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jong-Hee Chae, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of Warsaw</name>
      <address>
        <city>Warsaw</city>
        <zip>85- 822</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna Kostera-Pruszczyk</last_name>
      <phone>48 606 393 921</phone>
      <email>akostera@wum.edu.pl</email>
    </contact>
    <investigator>
      <last_name>Anna Kaminska, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Joan de Deu</name>
      <address>
        <city>Barcelona</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Sole Heuberger</last_name>
      <phone>+34 661 555 793</phone>
      <email>lsole@hsjdbcn.org</email>
    </contact>
    <investigator>
      <last_name>Andres Nascimento, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic la Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>M. Pilar Martí Martínez</last_name>
      <phone>+34 677 75 6564</phone>
      <email>mapifres@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jaun Vilchez Padilla, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Queen Silvia Children's Hospital</name>
      <address>
        <city>Goteburg</city>
        <zip>SE-416 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anna-Lena Gustafsson</last_name>
      <phone>46-31-3436069</phone>
      <email>anna-lena.m.gustafsson@vgregion.se</email>
    </contact>
    <investigator>
      <last_name>Mar Tulinius, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Astrid Lindgren Childrens Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monika Nordenbrand</last_name>
      <phone>46 8 517 77442</phone>
      <email>monika.nordenbrand@karolinska.se</email>
    </contact>
    <investigator>
      <last_name>Thomas Sejersen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHUV Lausanne</name>
      <address>
        <city>Lausanne</city>
        <zip>1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabina Rainy</last_name>
      <email>sabina.rainy@chuv.ch</email>
    </contact>
    <investigator>
      <last_name>Pierre-Yves Jeannet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hacettepe Childrens Hospital</name>
      <address>
        <city>Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Merve Oruc</last_name>
      <phone>0505 303 88 39</phone>
      <email>merveoruc87@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Haluk Topaloglu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erciyes University</name>
      <address>
        <city>Kayseri</city>
        <zip>38039</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Sefer Kumandas, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London Institute of Child Health</name>
      <address>
        <city>London</city>
        <zip>WC1N 1EH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabelle Wilson</last_name>
      <phone>0207 762 6892</phone>
      <email>isabelle.wilson@ucl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Francesco Muntoni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Manchester Children's Hospital</name>
      <address>
        <city>Manchester</city>
        <zip>M13 9WL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laura Crowther</last_name>
      <phone>0161 701 6918</phone>
      <email>laura.crowther@cmft.nhs.uk</email>
    </contact>
    <investigator>
      <last_name>Imelda Hughes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Newcastle upon Tyne Hospitals, NHS Foundation Trust</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 3BZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becky Davis</last_name>
      <phone>0191 241 8649</phone>
      <email>becky.davis@ncl.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Michela Guglieri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Switzerland</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.ptcbio.com</url>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 14, 2014</lastchanged_date>
  <firstreceived_date>March 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Duchenne muscular dystrophy</keyword>
  <keyword>Dystrophinopathy</keyword>
  <keyword>Nonsense mutation</keyword>
  <keyword>Premature stop codon</keyword>
  <keyword>Becker muscular dystrophy</keyword>
  <keyword>DMD/BMD</keyword>
  <keyword>PTC124</keyword>
  <keyword>Ataluren</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
    <mesh_term>Genetic Diseases, Inborn</mesh_term>
    <mesh_term>Muscular Diseases</mesh_term>
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Musculoskeletal Diseases</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
    <mesh_term>Neuromuscular Diseases</mesh_term>
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Muscular Disorders, Atrophic</mesh_term>
    <mesh_term>Genetic Diseases, X-Linked</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
